Previous 10 | Next 10 |
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
Mesoblast (MESO) provides an update on its pipeline of late-stage product candidates and an activity report for fiscal Q2 ended December 31, 2020. Revenues from royalties on TEMCELL HS Inj. sales for FQ2 were $2.1M compared to $2M in 2019.After availability of 60-day results of the ...
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the second quarter ended Dece...
Mesoblast's Phase 3 trial in Chronic Heart Failure failed to meet its primary endpoint. We believe Mesoblast's stated positive results in the failed CHF trial used statistical methods and post-hoc analysis that the FDA advises against. We believe the COVID-19-related ARDS trial wa...
Bit Digital (BTBT) -19%.TransEnterix (TRXC) -17% on $31.25M registered direct equity offering.Avinger (AVGR) -12%.LM Funding America (LMFA) -12%.GeoVax Labs (GOVX) -10%.Mesoblast (MESO) -10% after presenting heart failure Phase 3 trial results at Investor Healthcare Conference....
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 tr...
Mesoblast (NASDAQ: MESO) started the week on a strong note. Shares of the biotech soared by as much as 58.2% on Monday and closed the day's trading session up by 31.6%. Investors bid up Mesoblast's stock today because the company announced additional positive results from a clinical...
Gainers: Zomedica (ZOM) +86%.GeoVax Labs (GOVX) +67%.TransEnterix (TRXC) +65%.Sify Technologies (SIFY) +51%.Mesoblast (MESO) +45%.LM Funding America (LMFA) +36%.Aileron Therapeutics (ALRN) +32%.Energous (WATT) +31%.Acasti Pharma (ACST) +30%.Impinj (PI) +29%.Losers: Applied...
Gainers: GeoVax Labs (GOVX) +83%, Zomedica (ZOM) +82%, TransEnterix (TRXC) +49%, Mesoblast (MESO) +40%, Aileron Therapeutics (ALRN) +29%.Losers: Editas Medicine (EDIT) -16%, Medigus (MDGS) -15%, Jaguar Health (JAGX) -11%, Invita...
Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19 host genome structur...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...